Sergio Cifuentes Canabal/LinkedIn
Nov 8, 2024, 16:10
Sergio Cifuentes Canaval: Predictors of Response to CDK4/6i Rechallenge in ER+ Metastatic Breast Cancer
Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT Mexico, posted on LinkedIn:
“Predictors of Response to CDK4/6i Rechallenge in ER+ Metastatic Breast Cancer
This retrospective study, despite its limitations, addresses an often-posed question in clinical practice that remains unresolved by randomized trials. Changing CDK4/6i after progression on initial treatment is a common strategy, driven by both the trust in the first-line CDK4/6i approach and the limited efficacy or availability of subsequent options. This analysis offers reassurance regarding this practice and highlights the potential utility of molecular profiling for better decision-making.”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 8, 2024, 16:08
Nov 8, 2024, 15:56
Nov 8, 2024, 15:37
Nov 8, 2024, 15:35
Nov 8, 2024, 15:33